How did Johnson & Johnson perform?

JNJ posted revenue of $22.8 billion and EPS of $2.82.

Which stock is better for defensive investing?

Both are suitable; Walmart offers steadier growth, while JNJ focuses on medical innovation.

Walmart vs Johnson & Johnson: Two Defensive Plays, One Winner?

Walmart and Johnson & Johnson both beat estimates last quarter, but their divergent capital allocation strategies reveal different paths for defensive investors.

July 15, 2026

1 min read

Source: 24/7 Wall St.

Key Numbers

WMT revenue

165.5B

JNJ revenue

22.8B

WMT EPS

1.80

JNJ EPS

2.82

Both Walmart (WMT) and Johnson & Johnson (JNJ) exceeded earnings expectations last quarter, but their capital expenditure strategies tell two different stories about where defensive investing pays off.

Recommendation Change

No official analyst rating changes have been made yet, but the analysis highlights Walmart's focus on e-commerce and logistics versus JNJ's heavy R&D spending in healthcare.

Analyst Rationale

Analysts note that Walmart leverages its retail strength to improve operational efficiency and market share, while JNJ bets on pharmaceutical and medical device innovation for long-term growth.

Context

Walmart's stock rose 8% over the past month, while JNJ's fell 2%, reflecting market preference for Walmart's expansion strategy.

What We Conclude

Both stocks are defensive plays, but Walmart may appeal more for steady revenue growth, while JNJ offers diversification in medical products.

Frequently Asked Questions

Walmart reported revenue of $165.5 billion, beating estimates.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.